Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06436157Recruiting
Genetic testing support through a nurse-led program
This study tests whether a special program led by oncology nurses can help more people with solid tumor cancers get genetic testing. If you are starting a new treatment and have not had genetic testing before, this program may help you learn about your cancer risks and treatment options.
Chico, CaliforniaAges 18 years+ - NCT06439888RecruitingPhase 1/Phase 2
Immune cells plus radiation for limited-stage cancer spread
This trial tests whether giving immune-supporting cells (lymphocytes) alongside focused radiation (SBRT) can help control limited cancer spread. People with 1 to 5 small tumors that can all be radiated within two weeks may be eligible.
LyonAges 18 years+ - NCT06310382RecruitingPhase 1/Phase 2
Study of GH55 for cancers with MAPK mutations
This trial tests a new drug, GH55, for people with advanced solid tumors that have a specific change in a group of genes called MAPK. It is for those who have tried other treatments or cannot have standard therapy. The goal is to see if the drug is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
New Haven, ConnecticutAges 18 years+ - NCT07290088RecruitingPhase 2/Phase 3
Testing a new drug for advanced solid tumors
This trial tests a new drug called PRL3-zumab for people with advanced solid tumors (cancers that have spread). The goal is to see if it can shrink tumors or slow their growth. It is an option for patients who have had limited prior treatments.
Kota BharuAges 18–75 - NCT06739395RecruitingPhase 2
Precision cancer trial for patients out of standard options
This trial uses genetic testing of your tumor to match you with a targeted therapy. It is for people with advanced solid tumors who have exhausted or cannot tolerate standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07483554RecruitingPhase 2
IBI343 combination therapy for advanced solid tumors
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT06292208RecruitingPhase 1/Phase 2
Testing IBD0333 for advanced solid tumors or lymphoma
This trial tests an experimental drug called IBD0333 for people with advanced solid tumors or lymphoma who have run out of standard options. The drug targets a protein called 4-1BB to help your immune system fight cancer.
Jinan, ShandongAges 18–80 - NCT07027488RecruitingPhase 1
Testing AB821 for advanced solid tumors that resist immunotherapy
This trial tests a new study drug, AB821, for people with advanced solid tumors that have stopped responding to standard treatments, especially immunotherapy. The goal is to see if AB821 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT06763159RecruitingPhase 1
Study of HS-20124 for advanced solid tumors
This study tests a new drug called HS-20124 for people with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07269145RecruitingPhase 1
Testing TQB3122 capsules in advanced solid tumors
This trial tests an experimental oral capsule (TQB3122) for safety and early signs of effectiveness in people with advanced solid tumors that have not responded to standard therapies. It is for patients who are relatively healthy and have specific cancer types like ovarian, breast, or prostate cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07479667RecruitingPhase 1
Targeted immune cell therapy for solid tumors after surgery and chemo
This trial tests a new type of immune cell therapy (dendritic cells) that is designed to target specific proteins found on cancer cells. It is for people with certain solid tumors who have already had surgery and at least 4 cycles of standard chemotherapy after surgery.
ShanghaiAges 18–80 - NCT06155084RecruitingPhase 1/Phase 2
HP518 for advanced prostate cancer that has spread
This trial tests an oral drug called HP518 for men with a specific genetic change in their prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. The goal is to see if HP518 can control the cancer.
Hefei, AnhuiAges 18 years+ - NCT07508306Recruiting
Blue dye sentinel node mapping for early ovarian cancer
This study is testing a blue dye called Patent Blue to see if it can help surgeons find sentinel lymph nodes (the first nodes cancer might spread to) during surgery for early-stage ovarian cancer. The goal is to reduce the need for more extensive lymph node removal, possibly leading to fewer side effects.
La RabtaAges 18 years+ - NCT06469268Recruiting
Mobile app for managing cancer symptoms during chemo
This study tests a mobile app (ePRO) that helps you report symptoms and side effects during cancer treatment. It is designed for people receiving chemotherapy with cisplatin or oxaliplatin.
Beijing, Beijing MunicipalityAges Any age - NCT05761223RecruitingPhase 1/Phase 2
Study of FB849 for adults with measurable cancer lesions
This early-stage trial tests whether FB849 is safe and tolerable, how the body handles it, and whether it shows any early signs of helping cancer. You may be able to join if you’re an adult with at least one measurable tumor spot and your health tests meet study requirements.
Cleveland, OhioAges 18 years+ - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07187908RecruitingPhase 2
Study of Efbemalenograstim Alfa to prevent low white blood cell counts in cancer patients
This trial tests if a drug called Efbemalenograstim Alfa can help prevent a serious drop in white blood cells (febrile neutropenia) during chemotherapy. It is for patients with solid tumors who have a high or intermediate risk of this condition.
Zhengzhou, HenanAges 18–75 - NCT07662018Recruiting
Study of stem cell transplant after chemo for children with germ cell tumors
This study looks at how well a stem cell transplant works after a specific combination of chemotherapy drugs (gemcitabine, docetaxel, melphalan, and carboplatin) in children and young adults up to age 21 whose germ cell tumors have come back or not responded to treatment. It may help doctors understand who benefits most from this approach.
Houston, TexasAges 21 years+ - NCT06060769Recruiting
MRI risk assessment for liver cancer in chronic liver disease
This study uses special MRI scans to better predict liver cancer risk in people with chronic liver disease. It may help doctors identify high-risk patients earlier and improve monitoring.
Zhuhai, GuangdongAges 18 years+ - NCT06408402Recruiting
Environment and tumor risk in SDHx carriers
This study looks at whether things in the environment (like chemicals or lifestyle) affect the risk of developing certain tumors in people who have a change in their SDHx gene. It compares people with the gene change who have had a related tumor to those who haven't.
AngersAges 18 years+ - NCT07174453RecruitingPhase 3
Comparing side effects of different doses of immunotherapy
This study compares standard dosing schedules of pembrolizumab or nivolumab (two immunotherapy drugs) to see which one causes fewer immune-related side effects. It is for people with solid tumors who are already eligible to receive one of these drugs as part of their standard care.
Westwood, KansasAges 18 years+ - NCT06243354RecruitingPhase 1/Phase 2
Study of HYP-2090PTSA for KRAS-mutated advanced solid tumors
This trial tests a new targeted pill called HYP-2090PTSA for people with advanced solid tumors that have a specific KRAS mutation. The goal is to see if the drug can shrink tumors or slow their growth.
Fuzhou, FujianAges 18 years+ - NCT06454955RecruitingEarly Phase 1
PET scan imaging study for solid tumors using a new probe
This trial tests a new imaging agent that targets a protein called B7-H3 found on many solid tumors. It uses PET/CT to help doctors see and stage tumors more clearly.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,417 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.